touchPANEL DISCUSSION Targeting IL-1β in NSCLC: What does the future hold?
Watch a panel of experts discuss immunotherapy for non-small cell lung cancer (NSCLC) and the possible future role of interleukin-1β (IL-1β) blockade.
Dr Pilar Garrido
University Hospital Ramón y Cajal, Madrid, Spain
Chair Dr Pilar Garrido introduces the expert panel and agenda for this discussion on immunotherapy and targeting IL-1β in NSCLC.view bio and disclosures 1/4 Next Chapter
Immunotherapy for NSCLC today: Where are we?
The panel discusses current and future use of checkpoint inhibitors in NSCLC and how to identify patients with NSCLC who may benefit from treatment with a checkpoint inhibitor.view bio and disclosures 2/4 Next Chapter
What is the rationale for targeting IL-1β in NSCLC and which agents are currently in clinical development?
The panel discusses the rationale for targeting IL-1β in NSCLC and gives an overview of the agents that are in development.view bio and disclosures 3/4 Next Chapter
How can IL-1β inhibition be implemented in the management of NSCLC?
The panel discusses how IL-1β-targeting agents may be implemented in clinical practice if they are approved for NSCLC, including possible adverse events and biomarkers that may be used to identify patients who may benefit from IL-1β inhibition.view bio and disclosures 4/4 Leave Feedback
Learning Objectives & Overview
In this activity, three internationally renowned experts discuss the current use of checkpoint inhibitors in the management of NSCLC and how their role may evolve in the future. They also consider the rationale for targeting IL-1β and how IL-1β blockade may be implemented in clinical practice.
After watching this activity, participants should be better able to:
- Discuss the use of checkpoint inhibitors as immunotherapy for NSCLC and recognize their limitations
- Recall the rationale for targeting IL-1β in cancer immunotherapy and the IL-1β-targeted agents currently in clinical development for solid tumours
- Describe the clinical trials and data for IL-1β-targeting agents in NSCLC and consider how they may be used in clinical practice if approved
Faculty & Disclosures
Dr Pilar Garrido
University Hospital Ramón y Cajal, Madrid, Spain
Pilar Garrido is Associate Professor of Medical Oncology at the University of Alcalá, Madrid, Spain and serves as Head of the Thoracic Tumours Section in the Medical Oncology Department at the University Hospital Ramón y Cajal in Madrid, Spain.
Dr Garrido is Co-director of the Cancer and Chronic Disease Research Group at Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), where her main areas of research and clinical interest are thoracic tumours, in particular multimodality management, predictive biomarkers, immunotherapy and new anticancer agents in lung cancer. Dr Garrido is in charge of teaching and patient care, and is also actively involved in a number of phase I–III lung cancer clinical trials. She is an active member of CIBERONC, a Spanish Ministry of Health Network of clinical and translational research, where she is building a translational programme in collaboration with other clinical and experimental biology Spanish cancer groups.
Dr Garrido is the author of several peer-reviewed manuscripts and book chapters. She serves on the editorial board of different journals, including Annals of Oncology, and has presented her work nationally and internationally.
Dr Garrido is President of FACME (Spanish Federation of Medical Societies), she was the first woman president of the Spanish Medical Oncology Society and currently participates on a variety of national scientific committees including the Spanish National Cancer Strategy Committee.
She is a member of the ESMO (European Society for Medical Oncology) Council and Chair of the Women For Oncology Committee, she is also a member of the ESMO Fellowship and Award Committee, and the ESMO Press and Media Affairs Committee. She is a IASLC (International Association for the Study of Lung Cancer) Women in Thoracic Oncology Working Group Member, 2021 ASCO (American Society of Clinical Oncology) Annual Meeting Education Committee Member and an ESMO Faculty for lung tumours.
Dr Pilar Garrido discloses: Advisory role fees from AbbVie, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, GlaxoSmithKline, Janssen, Lilly, MSD, Novartis, Pfizer, Roche and Takeda. Speaker fees from AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, MSD, Novartis, Pfizer, Roche and Takeda.
Dr Barbara Melosky
University of British Columbia and BC Cancer, Vancouver, Canada
Barbara Melosky is a Clinical Professor of Medicine at the University of British Columbia and a Medical Oncologist at the BC Cancer Center in Vancouver, Canada. She graduated from medical school at the University of Manitoba and completed a residency in internal medicine and a fellowship in oncology at the University of British Columbia. Dr Melosky specializes in thoracic malignancies.
She is Head of the Lung Tumour Group in the province of British Columbia. Dr Melosky sits on the Executive Lung Site Committee for the Canadian Cancer Trials Group (CCTG). She has chaired the annual Canadian Lung Cancer Conference, attended by over 375 participants, for the last 20 years. She is proud to have started and built the British Columbia Lung Cancer Biobank, which is actively used for research by all who are interested.
She has published extensively and is considered a national and international expert on thoracic malignancies.
Dr Barbara Melosky discloses: Advisory role fees from AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Merck, Pfizer, Novartis and Roche. Speaker’s Bureau fees from AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Novartis and Roche.
Dr Alastair Greystoke
Freeman Hospital, Newcastle upon Tyne, UK
Alastair Greystoke is a Clinical Senior Lecturer and Honorary Consultant at Freeman Hospital, Newcastle upon Tyne, UK.
Dr Greystoke joined Newcastle University and the Northern Centre for Cancer Care in 2014. He is one of three consultants that run the Sir Bobby Robson Early Clinical Trials Centre at the Freeman Hospital and he has a special interest in the development of new anti-cancer drugs for patients with thoracic malignancies. In addition, he is the Clinical Lead for Cancer for the Yorkshire, Hull and North East England Genomic Laboratory Hub, the Joint Chief Investigator of the CONCORDE platform (adding in new drugs to radical radiotherapy in lung cancer), and leads the Pharmacodynamic Biomarker team at Newcastle University.
Dr Alastair Greystoke discloses: Consultancy/speaker fees from AstraZeneca, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, MSD, Novartis, Pfizer, Lilly, Roche and Takeda. Research funding from AstraZeneca.
Register to touchONCOLOGY for FREE
- Peer-reviewed journals and expert opinions
- Interactive CME and e-learning modules
- Video conference highlights